Top Message
About us
- Company Overview/ History
-
Top Message
- Leadership
INDEX
Top Message

Akimitsu Hirai
President and CEO
What is the future? Is it simply "that which has yet to come"? No, it is "that which is not yet seen, but is soon to arrive." C4U is a company that is pioneering the future of medicine and industry with its own hands.
At the core of our technology is genome editing. Genome editing is a technique that can precisely target the genes of humans and various organisms, allowing us to cleave or modify specific sections of their genetic code. While various gene-related technologies, such as genetic recombination, have existed, they were unable to precisely determine where modifications should be made. In this sense, genome editing represents a completely new and safe approach to gene modifications.
This type of genome editing technology has the potential to bring unprecedented benefits to humanity. For example, in the field of disease treatment, most medicines, aside from a few novel ones, have only been able to alleviate symptoms rather than provide a cure. In particular, for serious conditions such as genetic disorders, a complete cure has traditionally remained out of reach. However, by using genome editing technology to modify the specific genetic segments where problems have arisen, it becomes possible to cure such diseases and save the lives of patients.
In addition to treating diseases, it will be possible to find new varieties of plants by modifying the genes they already possess, using the same methods as conventional breeding, but faster and more precise. This new breeding will make a significant contribution to humanity through food, which is linked to the SDGs.
The mission and great advantage of a venture company is to quickly realize innovation, and that innovation will lead to the betterment of society.
C4U continues its research and development based on CRISPR-Cas3, a genome editing technology, to build such a "future" of society that is more prosperous and closer to humanity.

Tomoji Mashimo, Ph.D.
External Director CSO/ Inventor/ Founder
Imagine going to a hospital, having cream applied to your arm, and being told, "There, your disease is cured," with the treatment ending there.
With genome editing, such a future might be possible. The technology that holds the potential to make this dream-like future a reality is genome editing technology, "CRISPR-Cas3."
CRISPR-Cas3 is a versatile technology with a wide range of potential applications. In the field of agriculture, it can produce crops that can be grown even in disease-stricken and harsh environments, as well as livestock and aquatic products with large edible portions. This could one day solve the world's food problems and save millions from starvation. In the industrial field, it can also be applied to energy technology, etc. This could one day be able to deliver much-needed energy to underdeveloped countries and underprivileged people.
In the near future, gene therapy will be a viable treatment option for many people suffering from genetic diseases. There are numerous intractable diseases in the world that are not responsive to drug treatments or conventional therapies. This gene therapy, based on genome editing, represents a revolutionary new approach. This technology has the potential to cure many patients and save lives that would otherwise be lost.
We aim to raise awareness of the remarkable capabilities and high safety of CRISPR-Cas3 technology, with the goal of having it widely used across various fields and contributing to the advancement of industries.
We want to open the door to genome editing, which is a hurdle to overcome, as much as possible. We would like to play a window role in this regard.